Cationic Glyco-nangels for Epidermal Growth Factor Receptor (EGFR) specific siRNA delivery in Ovarian Cancer Cells

Marya Ahmed†, Phanphen Wattanaarsakit§, Ravin Narain†∗

†Department of Chemical and Materials Engineering, University of Alberta, Edmonton, AB, T6G 2G6, Canada

§Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Phyathai Road, Pathumwan, Bangkok, Thailand
Table S1. Preparation of nanogels

<table>
<thead>
<tr>
<th>Nanogels</th>
<th>PEGMA or NIPAM (mg)</th>
<th>AEMA (mg)</th>
<th>Macro-CTAs (mg)</th>
<th>CL (mg)</th>
<th>ACVA (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NGA1</td>
<td>301</td>
<td>66</td>
<td>380</td>
<td>60</td>
<td>2</td>
</tr>
<tr>
<td>NGA2</td>
<td>200</td>
<td>73</td>
<td>165</td>
<td>133</td>
<td>1.6</td>
</tr>
</tbody>
</table>
**NGA1: GAEMA\textsubscript{63-}b-(MeODEGM-st-AEMA-st-CL)\textsubscript{100}**

![Image of DNA bands for NGA1](image1)

**NGA2: GAPMA\textsubscript{57-}b-(NIPAM-st-AEMA-st-CL)\textsubscript{200}**

![Image of DNA bands for NGA2](image2)

Figure S1: Complexation of β-galactosidase DNA with cationic glyco-nanogels, at varying w/w ratios.
Figure S2: Size of nanogel-siRNA complexes in OMEM media in the absence and presence of serum proteins, as determined by DLS analysis.